JAZZ
ZYMEpartner · Not moving with the group now
Filing receipt · JAZZ / ZYME
“We have entered into separate collaboration and license agreements with BeOne Medicines Ltd.”
ZYME · partner
Confirmed
Biotech Cancer Therapies
15 names are moving together; 53% are participating in the current session.
1 observed Confirmed episode
Co-movement
Observed member paths adjusted against SPY. Shading marks the latest observation window.
Members
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| ZYME | Zymeworks Inc. | Healthcare | -3.5% | 1/3 observed active sessions |
| BHVN | Biohaven Ltd. | Healthcare | -2.2% | Group member |
| IONS | Ionis Pharmaceuticals, Inc. | Healthcare | -2.6% | Group member |
| DNTH | Dianthus Therapeutics, Inc. | Healthcare | +1.2% | Group member |
| SNDX | Syndax Pharmaceuticals, Inc. | Healthcare | -3.1% | 1/3 observed active sessions |
| EXEL | Exelixis, Inc. | Healthcare | -0.8% | Group member |
| RLMD | Relmada Therapeutics, Inc. | Healthcare | +0.6% | 1/3 observed active sessions |
| XENE | Xenon Pharmaceuticals Inc. | Healthcare | -1.7% | 2/3 observed active sessions |
| ABVX | Abivax SA | Healthcare | -2.8% | 1/3 observed active sessions |
| AXSM | Axsome Therapeutics, Inc. | Healthcare | -2.3% | 2/3 observed active sessions |
| ARGX | argenx SE | Healthcare | -0.2% | Group member |
| PHVS | Pharvaris N.V. | Healthcare | -0.3% | 1/3 observed active sessions |
| PRAX | Praxis Precision Medicines, Inc | Healthcare | -3.0% | 1/3 observed active sessions |
| ALNY | Alnylam Pharmaceuticals, Inc. | Healthcare | -3.6% | 1/3 observed active sessions |
| MDGL | Madrigal Pharmaceuticals, Inc. | Healthcare | -0.9% | Group member |
Why we believe this
Cohort
15 namesParticipation
53% this sessionObserved history
3 daily buildsThis identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
Connected, outside the group
RPRX
IONSinvestee · Not moving with the group now
Filing receipt · RPRX / IONS
“These amounts are related to the Royalty Pharma Investments, or Royalty Pharma, transaction, in which we sold a minority interest in our future SPINRAZA and pelacarsen r…”
IONS · investee
NVS
IONSpartner · Not moving with the group now
Filing receipt · NVS / IONS
“Our partner, Novartis, is responsible for ongoing development and commercialization of pelacarsen worldwide.”
IONS · partner
MRK
EXELpartner · Moving with the group now · 115 min observed
Filing receipt · MRK / EXEL
“To further expand our exploration of the clinical potential of zanzalintinib, we entered into a clinical development collaboration with Merck, known as MSD outside of th…”
EXEL · partner
TAK
EXELcustomer · Not moving with the group now
Filing receipt · TAK / EXEL
“During the three months ended March 31, 2026, we recognized $7.7 million in revenues in connection with an $8.0 million commercial milestone payment from Takeda, which w…”
EXEL · customer
History
2026-07-07 → 2026-07-133 observed active sessions · 0% of active names held across the episode